Tag: urology

IRVING, Texas – Strive Medical, a portfolio company of NMS Capital, has acquired the urology division of United States Medical Supply, strengthening its national footprint.  Strive Medical is a specialty provider of urology, wound care and other disposable medical supplies that has contracts with more than 24 state Medicaid programs and more than 5,000 private insurance plans.  “This transaction marks an important step in advancing Strive’s commitment to investing...

Lisa Wells, vice president of marketing at Cure Medical, has been appointed to the board of directors of the Spina Bifida Association. “She's a long-term supporter of our work and mission, and we know that her extensive knowledge of the issues facing the Spina Bifida community will enrich and enhance our shared goals,” said Sara Struwe, president and CEO of the association. Wells, who has more than 20 years of experience in public relations, marketing communications and web-based product...

WAYNE, Pa. - Teleflex will buy NeoTract for $1.1 billion in a move that significantly expands its urological product offerings, the company announced Sept. 5.NeoTract, maker of the UroLift System, had revenues of about $51 million in 2016 compared to about $18 million in 2015, representing 178% year-over-year growth. For 2017, NeoTract expects revenues to be between $115 million and $120 million, and for 2018, it expects them to grow at least 40%.“This combination is expected to solidify Teleflex's...

MINNEAPOLIS - Coloplast says its integration of Comfort Medical continues to “progress to plan” and its U.S. chronic care business saw double-digit organic sales growth in the third quarter. The company, which has its U.S. headquarters here but is based in Denmark, announced last year that it was buying Coral Springs, Fla.-based Comfort Medical for $160 million in cash, combining a manufacturer of ostomy, urology, continence and wound care supplies with a provider of those supplies. Overall,...

MURRAY HILL, N.J. - C.R. Bard and Rochester Medical, two players in the urology market, announced Sept. 4 that they have entered into an agreement to merge. The deal is expected to close later this year, with Bard paying $20 per share, about $262 million, for Rochester. “Rochester's double-digit growth product portfolio, including their customer access programs, is a key building block in our strategy to access faster growing markets over the long-term,” stated Timothy Ring, Bard chairman...